Publication | Closed Access

Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

MedicineGeneration Egfr-tkisPathologyLong-term SurvivalBronchial NeoplasmUncommon Egfr MutationsCancer TreatmentOncologyRadiation OncologyLung CancerCancer Growth